Back to results

Massachusetts Institute of Technology

Capacity analysis, cycle time optimization, and supply chain strategy in multi-product biopharmaceutical manufacturing operations

Abstract

dc:description.abstract

Application of system optimization theory, supply chain principles, and capacity modeling are increasingly valuable tools for use in pharmaceutical manufacturing facilities. The dynamics of the pharmaceutical industry - market exclusivity, high margins, product integrity and contamination constraints - coupled with increasing cost pressures, demand for specialized products increase, and growing industry complexity makes analytical business decisions necessary to sustain competitive advantage. The united application of capacity modeling, system optimization, and supply chain analysis tools, paired with implementation strategies on a multi-product vaccine production system are detailed to address important business difficulties.

Degree

thesis:*
Department dc:contributor.department
Leaders for Global Operations Program at MIT
Grantor dc:publisher
Massachusetts Institute of Technology
Year dc:date.issued
2011

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Fetcho-Phillips, Kacey L. (Kacey Lynn)
Advisor dc:contributor.advisor
  • Andreas Schulz and Charles Cooney.

Subjects

dc:subject × 3

Rights

dc:rights
Statement dc:rights
  • M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.
Language dc:language.iso
eng

Identifiers

dc:identifier.*
Handle dc:identifier.uri
http://hdl.handle.net/1721.1/66071
OAI identifier oai:identifier
oai:dspace.mit.edu:1721.1/66071

Chain of custody

source
Harvested from
MIT
Base URL
dspace.mit.edu/oai/request
Last updated
2026-07-22
Source record
OAI-PMH GetRecord
citation

Fetcho-Phillips, Kacey L. (Kacey Lynn). Capacity analysis, cycle time optimization, and supply chain strategy in multi-product biopharmaceutical manufacturing operations. Massachusetts Institute of Technology, 2011. http://hdl.handle.net/1721.1/66071